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Background: Appendicular osteosarcoma is the most common malignant primary canine bone tumor. When
treated by amputation or tumor removal alone, median survival times (MST) do not exceed 5 months, with the
majority of dogs suffering from metastatic disease. This period can be extended with adequate local intervention
and adjuvant chemotherapy, which has become common practice. Several prognostic factors have been reported
in many different studies, e.g. age, breed, weight, sex, neuter status, location of tumor, serum alkaline phosphatase
(SALP), bone alkaline phosphatase (BALP), infection, percentage of bone length affected, histological grade or
histological subtype of tumor. Most of these factors are, however, only reported as confounding factors in larger
studies. Insight in truly significant prognostic factors at time of diagnosis may contribute to tailoring adjuvant
therapy for individual dogs suffering from osteosarcoma. The objective of this study was to systematically review
the prognostic factors that are described for canine appendicular osteosarcoma and validate their scientific
importance.
Results: A literature review was performed on selected studies and eligible data were extracted. Meta-analyses
were done for two of the three selected possible prognostic factors (SALP and location), looking at both survival
time (ST) and disease free interval (DFI). The third factor (age) was studied in a qualitative manner. Both elevated
SALP level and the (proximal) humerus as location of the primary tumor are significant negative prognostic factors
for both ST and DFI in dogs with appendicular osteosarcoma. Increasing age was associated with shorter ST and
DFI, however, was not statistically significant because information of this factor was available in only a limited
number of papers.
Conclusions: Elevated SALP and proximal humeral location are significant negative prognosticators for canine
osteosarcoma.
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Osteosarcoma (OS) is a malignant tumor of mesenchy-
mal origin that produces osteoid. OS accounts for ap-
proximately 85 % of all primary canine bone tumors and
is almost exclusively observed in large or giant breeds
[1-5]. There is anecdotal evidence suggesting that males
are more predisposed. The median age of onset of clin-
ical signs ranges from 8 to 10 years [5,6], although it also
occurs in younger dogs [7].* Correspondence: j.kirpensteijn@uu.nl
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reproduction in any medium, provided the orDogs are often presented with a history of lameness or
in some cases with a pathologic fracture of the affected
bone. Predilection sites are the weight-bearing regions of
the long bones (humerus, femur, radius, tibia and ulna)
[8] with approximately 25 % of tumors arising in the
axial skeleton including the flat bones of the skull, ribs,
vertebrae, sternum, and pelvis [9,10]. OS is an aggressive
and invasive neoplasm that causes local skeletal destruc-
tion and resulting in radiographic evidence of both
osteoproductive and osteolytic lesions. They are highly
metastatic, predominantly to the lungs with a lower fre-
quency of spread to distant bones, regional lymph nodes
[11] and other soft tissues [12,13]. A clinical diagnosis is
made following assessment of case signalment and his-
tory and based on the radiographic appearance of theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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histological examination with tumor classification based
on the formation of osteoid matrix with osteoblastic,
fibroblastic, chondroblastic, telangiectic and combined
subtypes [14,15]. There can be considerable variation in
the histological appearance both between and within
individual neoplasms, however, rendering histological
parameters less reproducible between studies.
Dogs with OS that were treated by amputation alone
have poor overall survival outcome: median overall sur-
vival times are typically less than five months, with the
majority suffering from metastatic disease [5,16,17].
Over the years, advances in disease management, includ-
ing ‘limb-sparing’ surgical and radioablative methods
used only to selectively eradicate tumors located in the
distal radius, ulna and tibia have been described [18,19].
Adjuvant therapy, such as multimodal chemotherapy
regimes, treatment with bisphosphonates or immune
modulators and palliative radiation, can also be provided
and are reported to improve clinical or survival outcome
[20-23]. Combination of therapy modalities and drugs
may contribute significantly to survival statistics but ran-
domized, double-blinded studies have not been per-
formed routinely.
There are many well-documented prognostic indica-
tors for canine OS, and the majority of these are sim-
ilar to those reported from large retrospective studies
on human OS, including tumor location, histologic
grade, certain biomarkers, the use of chemotherapy, etc.
[24-27]. The accurate segregation of canine patients into
distinct prognostic subgroups based on such indicators
is essential in the tailoring of appropriate treatment.
However, the required information is not always com-
pletely available in the existing literature and studies
report sometimes conflicting results. In this paper, we
perform a meta-analysis to estimate the combined effect
size over a number of studies of a selection of well-
described prognosticators.
The aims of the current study were to systematically
review the prognostic factors that are described for ca-
nine appendicular osteosarcoma and validate their scien-
tific importance. After validation, a meta-analysis was
performed on serum alkaline phosphatase (SALP),
tumor location and age at diagnosis to study the associ-
ation of these factors with survival time (ST) and disease
free interval (DFI).
Materials and methods
Search strategy and quality assessment
A search was performed using Medline (PubMed) and
Google Scholar search for all eligible studies performed
between January 1970 and May 2011. The following
search strategies were applied: [“canine”, “osteosarcoma”
and “prognosis”] and [“canine”, “osteosarcoma” and“survival”]. Reports were selected and carefully reviewed
that included canine stage <2B appendicular osteo-
sarcoma cases [18]. Additionally, all manuscripts were
evaluated for methodological quality according to a stan-
dardized questionnaire adapted from Bramer et al.
(2009) including variables such as institute where the
study was performed, year of publication, number of
cases reported (at least 5), whether the study was rando-
mized or not, study design, recorded survival end points,
univariate (uva) or multivariate analysis (mva), use of
control groups, listing of research period, completeness of
follow up information, method of follow up examination,
listing if cases were lost to follow up, definition of prog-
nostic factors, listing of therapy modalities and listing of
confounding factors. Two independent reviewers (JK, GS)
performed study selection, assessment of methodological
quality and data extraction. A third reviewer (IB) resolved
disagreements, if necessary.
Statistical analysis
Studies fulfilling one or two types of quality criteria were
selected for meta-analysis. First, only randomized
double-blind studies with multivariate data analysis were
selected. After that, non-randomized, prospective studies
were added to evaluate if additional significant factors
could be determined. Studies with similar dog popula-
tions, outcome variables, prognostic factors, follow-up
information, and adjustment for confounding variables
were combined. Adjusted relative risks were pooled with
a random effects model and assessed for statistical hetero-
geneity by Chi-square analysis. After establishment of het-
erogeneity, the source was determined by meta-analysis.
All meta-analyses were performed using commercial
statistical software (Comprehensive meta-analysis V2,
©2006 Biostat, Inc., Englewood, NJ, USA), which pro-
vides a table with relative risk for each study and a forest
plot. Both binary and continuous data were reported in
the selected papers. It was impossible to combine both
types of data in the same analysis; therefore for each vari-
able separate sub analyses were performed on the effect
measures hazard ratio (HR), median survival time (MST)
and median disease free interval (MDFI). The groups com-
pared for the variables SALP and location were as follows:
elevated SALP versus SALP within reference range at time
of diagnosis; (proximal) humerus compared to other loca-
tions in the appendicular skeleton. For age it was not pos-
sible to make two groups with the available data; factor
data were analysed in a qualitative manner.
Some studies reported univariate data analysis while
others reported multivariate data analysis, meaning that
a studied factor was corrected for therapy or other con-
founding factors analysed. Where possible, data of multi-
variate analysis were used. Where necessary, a (set of )
paper(s) was excluded to see if the overall effect changed.
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random-effects model was used, assuming that the true
study effect varies across studies and the observed study
effects reflect both this variation and random variation.
Selected studies that did not present the data in sufficient
detail were qualitatively summarized where necessary.
Results
Inclusion of papers
Through the searches, 821 papers were selected for
review of which 55 met the criteria to be included in the
study presented here (Additional file 1). No disagree-
ments needed to be resolved by the third reviewer. Of
the 55 studies, 16 were multicenter, and 39 monocenter,
of which the majority came from Colorado State Univer-
sity (17), Utrecht University (5), University of Wisconsin-
Madison and Tufts University (each 4). One study con-
tained two independent studies and was split in two
(Kurzman et al., 1995). One study was published in the
1970s, 5 in the 1980s, 14 in the 1990s and 35 in 2000–
2011. 14 Studies were considered randomized, 27 studies
were prospective, and 29 retrospective. Of all the studies,
only 5 were placebo controlled. The number of cases
varied from 11 to 303, with a mean of 61 ± 8. Outcome
variables included survival time in 51, disease free inter-
val in 32, metastasis free interval (MFI) in 13, and recur-
rence free interval (RFI) in 6 studies. Univariate analyses
were performed in all studies varying from Kaplan Meier
(KM) survival curves in 34, KM combined with (Cox)
regression analysis in 20, and one study mentioned an
ANOVA. Multivariate analysis was performed with a
multivariate cox proportional hazard analysis in 18 and
some other multivariate test in 7 reports. Historic con-
trol groups are common (n= 19) and some studies did
not use a control group at all. The time of evaluation
after the procedure and methodology varied too but
most studies evaluated the dogs every 2–3 months using
pulmonary radiography (n = 37); 13 studies did not in-
clude any information about follow up techniques. Most
studies failed to include how long these dogs needed to
be followed up (n = 39) or how many cases were lost to
follow up (n = 33). An abundance of treatments were
described, of which amputation combined with some
kind of chemotherapy was most common.
Significant factors
Many significant factors are described in the 55 papers
selected, e.g. age, breed, weight, sex, neuter status, loca-
tion of tumor, SALP, bone alkaline phosphatase (BAP),
infection, percentage of bone length affected, histological
grade or histological subtype of tumor. The effect of
SALP level, location (proximal humerus) and age at
diagnosis were reported most often in the 55 selected
papers and these factors were subjected to meta-analyses.Thirteen papers were included in the meta-analysis on
SALP and seven papers in the meta-analysis on (proximal)
humerus; some studies reported more than one variable.
For age it turned out to be difficult to find sufficient studies
with comparable selections of age categories to run meta-
analysis on, therefore in the results a qualitative summation
is given for all relevant age data found. Six papers reported
the effect of age as confounding factor using HR, MST or
MDFI, three papers did not give an estimate of the ef-




For the meta-analysis for SALP on survival time using
hazard ratios, data from seven studies were available. Six
of these studies used univariate analysis and one used
multivariate analysis. All studies combined, the meta-
analysis (Figure 1) on hazard ratios showed that dogs
with an elevated SALP level at time of diagnosis have
shorter survival times compared with dogs with a SALP
level within reference range, with a hazard ratio of 1.62
(95 % CI: 1.21–2.17). Leaving the one study with the
multivariate analysis (Phillips et al., 2009) out, the haz-
ard ratio dropped to 1.44 (95 % CI: 1.11–1.87). The sub-
analysis with median survival times (also seven studies)
showed that dogs with elevated SALP overall lived
156 days shorter (MST: -156) compared with dogs with
SALP within reference range (95 % CI: -209 to −104)
(Figure 2). When selecting only the studies with multi-
variate or univariate analysis the difference became
−132 days (95 % CI: -252 to −11) and −186 days (95 %
CI: -248 to −124), respectively.
Disease free interval
For the meta-analysis on disease-free interval ten papers
were used, of which the majority was also used for the
meta-analysis on survival time. The effect direction of
elevated SALP on DFI was comparable to that on ST.
Figure 3 shows an overall HR of 1.96 (95 % CI: 1.50–
2.56) for dogs with an elevated SALP level at time of
diagnosis. The two multivariate analyses (Sottnik et al.,
2010 and Phillips et al., 2009) together give a HR of 2.33
(95 % CI: 1.60–3.39) for elevated SALP level. Combining
only the univariate analyses, the HR dropped to 1.64
(95 % CI: 1.12–2.40). The difference in MDFI (here only
univariate analyses were available) was −123 days (95 %
CI: -166 to −79) (Figure 4).
Location - (proximal) humerus
Survival time
Four papers were used for the meta-analysis on ST for
location. Of these papers, one reported the humerus as a
whole as reference (Kow et al., 2008), the other three
Study name Sample size Statistics for each study Hazard ratio and 95%  CI
Hazard Lower Upper Relative Relative 








Saam 2010(uva) 63 0.900 0.437 1.854 -0.286 0.775
Selvarajah 2009(uva) 32 2.439 1.094 5.438 2.179 0.029
Philips 2009(mva) 138 2.270 1.437 3.586 3.513 0.000
Tham 2008(uva) 21 1.660 0.481 5.728 0.802 0.423
Kow 2008(uva) 67 2.160 1.003 4.651 1.968 0.049
Kirpensteijn 2002(uva) 99 1.802 1.003 3.238 1.970 0.049
Garzotto 2000(uva) 61 1.240 1.057 1.455 2.639 0.008
1.620 1.208 2.173  3.222 0.001 
0,1 0,2 0,5 1 2 5 10
Favours A Favours B
Meta Analysis
Meta Analysis
Figure 1 Meta-analysis of univariate and multivariate data sets for predictive value of serum alkaline phosphatase level on survival
time using hazard ratios.
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on all studies combined (Figure 5) showed that dogs
with the primary tumor located in their (proximal)
humerus had shorter survival times than dogs with
the primary tumor located elsewhere in their appendi-
cular skeleton (HR 1.86; 95 % CI: 1.34–2.57). We also
performed subset analyses on three subgroups (mva,
uva and proximal humerus) and found no large differ-
ences in effect between the subgroups; estimates for HR
varied between 1.82 and 2.21. The sub analysis on MST
(Figure 6, all manuscripts reporting uva) showed that
for (proximal) humerus the MST is 132 days shorter
compared with other locations (95 % CI: -211 to −52).
Approximately the same difference in MST (−131 days)Study name Sample size Statistics for each study
Difference Standard Lower Upper 
in means error Variance limit    limit Z-Value p-
Philips 2009(uva) 138 -241.000 64.942 4217.430 -368.283-113.717 -3.711 0
Kow 2008(uva) 48 -153.500 57.127 3263.451 -265.466 -41.534 -2.687 0
Moore 2007(mva)        293 -85.000 33.623 1130.519 -150.900 -19.100 -2.528 0
McNeill 2007(uva) 96 -157.000 59.715 3565.902 -274.040 -39.960 -2.629 0
Chun 2005(uva) 35 -135.000 141.503 20023.237 -412.342 142.342 -0.954 0
Vail 2002(uva) 40 -252.000 92.936 8637.010 -434.150 -69.850 -2.712 0
Garzotto 2000(mva) 61 -213.000 74.716 5582.525 -359.441 -66.559 -2.851 0
-156.407 26.686 712.120 -208.710-104.104 -5.861 0
Meta An
Meta Analysis
Figure 2 Meta-analysis of univariate and multivariate data sets for pr
survival time in days.applied for the sub analysis leaving out the proximal
humerus.
Disease Free Interval
For the meta-analysis on DFI for location, data from six
papers were used, three of which were also used for the
analyses on ST. The effect of (proximal) humerus as
location on DFI was comparable with the effect on ST.
Dogs with primary tumors located in the (proximal) hu-
merus had shorter DFIs compared with other locations
(HR 2.53; 95 % CI: 1.34–4.77) (Figure 7). The effect of
the proximal humerus in particular was comparable (HR
2.57; 95 % CI: 0.90–7.35). Performing the subanalysis
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edictive value of serum alkaline phosphatase level on median
Study name Sample size Statistics for each study Hazard ratio and 95% CI
Hazard Lower Upper Relative Relative 







Sottnik 2010(mva) 69 2.610 1.311 5.195 2.732 0.006
Selvarajah 2009(uva) 32 2.149 0.969 4.766 1.882 0.060
Phillips 2009(mva) 138 2.220 1.419 3.473 3.494 0.000
Tham 2008(uva) 21 1.510 0.483 4.724 0.708 0.479
Kow 2008(uva) 48 1.830 0.890 3.763 1.643 0.100
Kirpensteijn 2002(uva) 99 1.316 0.711 2.436 0.874 0.382
1.958 1.499 2.558 4.932 0.000
0,1 0,2 0,5 1 2 5 10
Favours A Favours B
Meta Analysis
Meta Analysis
Figure 3 Meta-analysis of univariate and multivariate data sets for predictive value of serum alkaline phosphatase level on median
disease free interval using hazard ratios.
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−73) (Figure 8). Subset analyses on proximal humerus
in particular and humerus as a whole showed MDFIs of
respectively −91 and −167 days.
Age
The papers analysing age as confounding factor all
reported different age categories and used different ef-
fect outcomes. As it did not occur that more than two
studies used both the same outcome type and the same
age categories, it appeared impossible to run a meta-
analysis on more than two studies. Therefore these data
are summarized in a qualitative manner in Table 1, 2
and 3.Study name Sample size Statistics for each study
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p
Sottnik 2010(uva) 69 -196.000 114.658 13146.515 -420.726 28.726 -1.709
Phillips 2009(uva) 155 -190.000 53.273 2838.018 -294.413 -85.587 -3.567
Thamm 2008(uva) 21 -134.000 159.054 25298.294 -445.741 177.741 -0.842
Kow 2008(uva) 67 -115.500 56.317 3171.638 -225.880 -5.120 -2.051
McNeill 2007(uva) 96 -118.000 53.550 2867.646 -222.957 -13.043 -2.204
Chun 2005(uva) 35 -142.000 384.140 147563.714 -894.901 610.901 -0.370
Hillers 2005(uva) 214 -78.000 34.553 1193.875 -145.722 -10.278 -2.257
Vail 2002(uva) 40 -357.000 144.379 20845.190 -639.977 -74.023 -2.473
-122.580 22.226 493.992 -166.142 -79.018 -5.515
Meta An
Meta Analysis
Figure 4 Meta-analysis of univariate and multivariate data sets for pr
disease free interval (in days).Survival time
The influence of age on ST reported in the eight papers
used is shown in Table 1 and 2. According to Saam et al.
(2011) and Phillips et al. (2009), dogs under the age of 5
showed longer MSTs compared with dogs over the age
of 5. This was comparable to the study of Liptak, et al.
(2006), which reported that older dogs had a signifi-
cantly shorter MST. In the study of Miller et al. (2009),
dogs older than 6 years showed a slightly increased HR
(but with insignificant p-value) compared with younger
dogs. The study of Kent et al. (2004) reported that the
age under the mean age in that study was not prognostic
for survival. According to Spodnick et al. (1992) dogs in
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Saam 2010(uva) 65 1.600 0.823 3.110 1.386 0.166
Phillips 2009(mva) 155 1.600 0.992 2.582 1.925 0.054
Kow 2008(uva) 67 2.220 1.088 4.530 2.192 0.028
Bergman 1996(mva) 48 4.014 1.348 11.951 2.497 0.013
1.859 1.343 2.574 3.734 0.000
0,1 0,2 0,5 1 2 5 10
Favours A Favours B
Meta Analysis
Meta Analysis
Figure 5 Meta-analysis of univariate and multivariate data sets for predictive value of location of tumor (LOC) on survival time using
hazard ratios.
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Concerning the continuous survival data; in the paper of
Selvarajah et al. (2009) age overall did not significantly
influence ST. Moore et al. (2007) reported that dogs
have significantly worse survival rates as age increases.
Overall, most studies performed in the last decennium
showed worse survival rates for dogs with increasing age
compared with younger dogs.
Disease free interval
Contradictory data were observed for DFI (Table 3).
According to the study of Sottnik et al. (2010), dogs
older than 8 years showed significantly longer MDFIs
compared with younger dogs. Phillips et al. (2009) on
the other hand reported that dogs older than 5 showed a
significantly increased HR for MDFI and significantly
shorter MDFIs compared with younger dogs. Miller
et al. (2009) also reported an increased HR for dogsStudy name Sample size Statistics for each study
Difference Standard Lower Upper 
in means error Variance limit limit Z-Value p-V
Saam 2010(uva) 65 -99.000 57.496 3305.747 -211.689 13.689 -1.722 0.
Phillips 2009(uva) 155 -165.000 58.716 3447.614 -280.082 -49.918 -2.810 0.
Kow2008(uva) 67 -140.000 227.247 51641.198 -585.396 305.396 -0.616 0.
-131.582 40.425 1634.191 -210.814 -52.350 -3.255 0.
Meta An
Meta Analysis
Figure 6 Meta-analysis of univariate data sets for predictive value ofolder than 6 years, however, not significantly. Last, in
the study of Kent et al. (2004) age under the mean age
was prognostic for DFI.
Discussion
This is the first paper published in veterinary literature
that compares outcomes in companion animal osteosar-
coma using meta-analysis confirming the significance of
three prognostic variables, including serum alkaline
phosphatase, location and age in this devastating tumor.
Serum ALP is a strong prognosticator
SALP is most likely the strongest prognostic indicator
for ST and DFI of canine OS and confirmed expectations
in the veterinary literature. Bone alkaline phosphatase is
a bone turnover marker measured in serum. It reflects
the increased turnover associated with bone destruc-
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Figure 7 Meta-analysis of multivariate data sets for predictive value of location of tumor (LOC) on median disease free interval using
hazard ratios.
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significance of serum total alkaline phosphatase activity
for human beings with osteosarcoma has been recog-
nized for over 30 years [29]. In most veterinary studies,
the total SALP is measured. Total SALP is easily quanti-
fiable and a routine diagnostic test in most veterinary
laboratories. Total SALP, however, consists of several
other isoenzymes, of which those derived from liver
(LALP) and bone (BALP) represent the majority in nor-
mal dogs. A corticosteroid-induced isoenzyme (CALP)
may be present in dogs with hyperadrenocorticism and
dogs receiving exogenous corticosteroids [30]. The prog-
nostic value of total SALP for human osteosarcoma is
limited by its lack of specificity for tumor tissue [31,32].
The enzyme’s activity may be increased by exogenous
corticosteroid administration or hyperadrenocorticism,










































Figure 8 Meta-analysis of univariate data sets for predictive value ofwhich may cause increases in LALP [31]. Measuring the
total SALP might therefore not always give reliable out-
comes. Measuring the bone ALP (BALP) seems more
logical, since in dogs with osteosarcoma, BALP is
expected and proven to be elevated and more discrimin-
ant than the other isoenzymes [33]. Serum BALP activity
was a direct reflection of osteoblastic activity [34] in
people. Additionally, the reference range for SALP in
dogs differs among various age groups [33,35] and
breeds [36], which could be another factor that may in-
fluence study results. The overall meta-analysis done in
this study for median ST showed a stronger significant
effect on HR than the analysis on only MVA or UVA
studies. This could be caused by confounding variables
that may be associated with SALP, including breed vari-






location of tumor (LOC) on median disease free interval (in days).
Table 1 Survival data on age of dogs with osteosarcoma








HR (95 % CI) p-value
Saam 2010
(UVA)








3 <6 (reference) 0.89
73 6-10 1.09 (0.21-5.68)
7 >10 1.14 (0.28-4.71)
Liptak 2006
(MVA)
20 Older* 2.06 (1.03-4.14) 0.042
Kent 2004
(UVA)
32 <mean age** 0.156
Spodnick 1992
(MVA)
162 7-10*** vs. <0.01
<7 and >10
UVA=univariate analysis; MVA=multivariate analysis; N = number;
MST =median survival time; HR = hazard ration; reference = the reference
group with which the others are compared.
*MST for older dogs was significantly decreased (median age 8.3 years, range
4.5-11 years).
**Only median age was mentioned in article (8.8 years, range 2.2-16.5 years)
***Longer survival time.
* MST for older dogs was significantly decreased (median age 8.3 years, range
4.5-11).
** Median age 8.8 years, range 2.2–16.5.
*** Longer ST.
Table 3 Disease free interval data on age of dogs with








HR (95% CI) P-value
Sottnik 2010
(UVA)
39 <=8 204 0.188
30 >8 345 0.59
Sottnik 2010
(MVA)
69 >8 vs. <=8 0.42 (0.21-0.85) 0.016
Phillips 2009
(UVA)




155 >5 vs. <5 2.1 (1.04-4.25) 0.038
Miller 2009
(UVA)
3 <6 (reference) 0.54
73 6-10 1.59 (0.33-7.71)




UVA=univariate analysis; MVA=multivariate analysis; N = number;
DFI = disease free interval; HR = hazard ration; reference = the reference group
with which the others are compared.
* DFI in this paper was stated as ‘progression free survival’.
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The most common human OS sites are the femur
(42 %), tibia (19 %), and humerus (10 %) [37]. The prox-
imal humerus, despite the fact that it is not the most
common site, was associated with poorer (metastasis-
free) survival [38,39] in man. In this study, the (prox-
imal) humerus was also shown to be the location with a
worse prognostic outcome for canine OS. One of the
reasons is the fact that tumors in this location may be
observed at a later stage compared to other locations
that are more clinically obvious.
The location with the best prognosis may also be
of clinical relevance for both canine and human OS,Table 2 Survival data on age of dogs with osteosarcoma







HR (95 % CI) p-value
Selvarajah 2009
(UVA)
32 Overall 1.137 (0.96-1.35) 0.147
Selvarajah 2009
(MVA)
32 Overall 204 1.18 (0.92-1.52) 0.202
Moore 2007
(MVA)
303 Increasing age 244* 0.004
* MST was recalculated from months (8) to days by multiplying with 30.5.however for canine OS this information was often not
available. In human OS, survival of patients with primary
malignant bone tumor of distal lower extremity seems to
be better than that of other sites [40]. This is comparable
to canine OS: in several canine studies, the radius is
cited as the location with the best prognosis for ST and
DFI [2,41-43].
Age may be prognostic in canine osteosarcoma
In human OS, a primary osteosarcoma in older patients
showed a poorer prognosis [38,44]. A predisposing fac-
tor in middle-aged to elderly people is Paget’s disease,
however. One of the most serious complications of
Paget’s disease is a significant increase in the incidence
of osteosarcoma [45]. Despite of the limited amount of
canine OS data available for age analyses, it seemed that
increasing age is an important prognostic factor for dogs
with appendicular OS. Survival time may not be the
most sensitive variable, however, because it can be con-
founded by various other medical problems that arise in
older dogs with malignant bone cancer. Additional stud-
ies comparing age categories need to be conducted using
more elaborate meta-analyses.
The role of adjuvant chemotherapy
Over the years, various compounds have been used in
adjuvant chemotherapy protocols against canine OSA
including cisplatin, carboplatin and doxorubicin. These
have been used in single and in multi-agent regimes and
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survival advantage of dogs receiving chemotherapy was
present compared to (historic) controls [46-49]. No
obvious differences in survival were observed when these
treatments were compared with pre- or post-operative
chemotherapy [50] and no differences in the DFI was
reported for dogs treated using single- or multi-agent
chemotherapeutic regimes. The prolonged, intense use
of chemotherapy is often not a valid option due to
adverse side effects compromising any clinical benefits
and decreasing client compliance [51]. To date, even
aggressive adjunctive therapy has proven ineffective in
restricting all growth of metastases. Additionally, a small
number of cases of canine OS that do not receive adju-
vant chemotherapy do not succumb to metastatic dis-
ease once the primary tumor has been removed [52].
This finding suggests that genetic composition of both
the host and tumor may be contributing to differences
in the metastatic potential. In human OS, the prognosis
has increased from 20 % 5-year survival in 1970 to 60 %
nowadays because of the various chemotherapeutic pro-
tocols [53]. The histological response to preoperative
chemotherapy was an important clinical predictor of the
result of operative treatment of human osteosarcoma
and was similarly important in one study by Powers et al
[54]. This indicator should be used to identify patients
who are at high risk for metastasis; as such patients may
be candidates for more intensive or novel therapy proto-
cols [42]. This important prognostic factor in human OS
may also be a very interesting factor to further investi-
gate in the canine OS but very few studies have reported
evaluation of this variable making meta-analysis cur-
rently impossible. Meta-analyses for this factor and for
different (types of) chemotherapy may be a valuable next
step to see which therapies give the most optimal results
for survival in canine appendicular osteosarcoma.
New insights, limitations and recommendations for
prognostic studies in canine OSA
Often scientific papers only report data when they are
found significant. Non-significant results are many times
only cited as ‘non significant’, yet the statistical data are
left out. To be able to perform a meta-analysis taking
into account all relevant data both significant and non-
significant outcomes are essential. Leaving out data may
result in an inadequate outcome. Unfortunately, not all
available papers could be used for the meta-analyses in
this study, since results were not always reported in suf-
ficient detail whereby essential data were missing (e.g.
sample size, confidence interval, HR or p-value).
For future reference, data should be coded in a man-
ner that allows comparison of various studies with com-
parable objectives. For instance, we observed that in
some studies data were coded as continuous variables, inother studies they are coded as binary data. Therefore,
the estimates of the effect size are difficult to compare.
When specific factors are coded >1, one would expect
them to be a negative prognostic factor. Once coded
<0 it would be a protective factor. This was sometimes
mixed up. For example, in the study of Phillips (2009)
elevated SALP was cited as ‘negative prognostic factor’,
yet the corresponding HR was 0.44. Since on the other
hand following uva analysis both ST and MST for dogs
with elevated SALP was shorter than for dogs with SALP
within reference range, it seemed that the HR should be
1/0.44 [55]. The paper of Sottnik, et al (2010) was not
completely clear whether the HR of 0.59 corresponded
to the age category ≤8 (which was the correspondent
category in the study or otherwise not stated clearly in
the relevant Table) or ≥8 years [56]. For the meta-analysis
in the current study the HR was linked to the category
≥8 years, since in the mva analysis the same category also
showed a HR <1 (0.42) and the MDFIs were also longer
for that specific category. Yet the range of the DFI (uva)
in the category ≤8 was extremely large which could mean
that the data are not completely reliable. All in all, the
systematic coding of risk factors in a consequent way
would be extremely helpful for future analyses.
Although many studies are performed, on account of
above-mentioned reasons it remains difficult or even im-
possible to compare these individual studies and signifi-
cantly prove that possible prognostic factors are really
prognostic. Only a few studies could be used for the
meta-analyses and of these studies it needs to be said
that we stretched to the limit the fact that the studies it-
self were comparable. This is a common and unavoid-
able fact for diseases that are relatively infrequent, such
as canine OS. Researchers should therefore be stimu-
lated to work together in the OS field, which is not only
interesting from a research point of view but also in in
the One Health approach of this comparable disease
between man and dog.
Conclusions
Both elevated SALP level and the (proximal) humerus as
location of the primary tumor are significant negative
prognostic factors for both ST and DFI in dogs with
appendicular osteosarcoma. Increasing age was asso-
ciated with shorter ST and DFI, however, was not statis-
tically significant because information of this factor was
available in only a limited number of papers. Multicen-
ter, well-designed research efforts are necessary to con-
found the message that should be relayed to clients and
patients to allow them to make an evidence-based deci-
sion in the treatment of their animal or child with this
type of malignant bone tumor. Multicenter studies are
only possible when researchers use the same variable
definitions and show all relevant results.
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